JP Morgan analyst Steven Alexopoulos maintains BankUnited (NYSE:BKU) with a Underweight and lowers the price target from $43 to $38.
Beam Therapeutics Q4 EPS $(0.54) Beats $(1.33) Estimate, Sales $20.04M Beat $12.53M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(1.33) by 59.4 percent. This is a 43.16 percent increase over losses of $(0.95) per share from
